AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home iLIVER Article
Article Link
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Commentary | Open Access

Comment on “Clinical outcomes and histologic findings of patients with hepatocellular carcinoma with durable partial response or durable stable disease after receiving atezolizumab plus bevacizumab”

Binghua Lia,1, Qiang Wangb,1, Weiwei Huc, Huan Lia, Peng Yana, Yajuan Caoa, Decai Yua( )
Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China
Department of Clinical Science, Intervention and Technology (CLINTEC), Division of Medical Imaging and Technology, Karolinska Institutet, Stockholm 14186, Sweden
Center for New Drug Safety Evaluation and Research, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 211198, China

1 Co-first authors, with equal contributions.

Show Author Information

References

[1]

Shen YC, Liu TH, Nicholas A, et al. Clinical outcomes and histologic findings of patients with hepatocellular carcinoma with durable partial response or durable stable disease after receiving atezolizumab plus bevacizumab. J Clin Oncol 2024: JCO2400645. https://doi.org/10.1200/JCO.24.00645.
Crossref Google Scholar
[2]

Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020;382(20):1894–905. https://doi.org/10.1056/NEJMoa1915745.
Crossref Google Scholar
[3]

Donne R, Lujambio A. The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma. Hepatology 2023;77(5):1773–96. https://doi.org/10.1002/hep.32740.
Crossref Google Scholar
[4]
European Medicines Agency. Guideline on adjustment for baseline covariates in clinical trials. The Netherlands: European Medicines Agency; 2015. Available online: https://www.ema.europa.eu/en/adjustment-baseline-covariates-clinical-trials-scientific-guideline.
[5]

Borcoman E, Kanjanapan Y, Champiat S, et al. Novel patterns of response under immunotherapy. Ann Oncol 2019;30(3):385–96. https://doi.org/10.1093/annonc/mdz003.
Crossref Google Scholar
[6]

Murad MH, Sultan S, Haffar S, et al. Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med 2018;23(2):60–3. https://doi.org/10.1136/bmjebm-2017-110853.
Crossref Google Scholar
[7]

Xu B, Dong SY, Bai XL, et al. Tumor radiomic features on pretreatment MRI to predict response to lenvatinib plus an anti-PD-1 antibody in advanced hepatocellular carcinoma: a multicenter study. Liver Cancer 2022;12(3):262–76. https://doi.org/10.1159/000528034.
Crossref Google Scholar
[8]

Iwamoto H, Shimose S, Niizeki T, et al. Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma. Clin Mol Hepatol 2022;28(3):575–9. https://doi.org/10.3350/cmh.2022.0047.
Crossref Google Scholar
[9]

Sato S, Aoki T, Matsumoto T, et al. Pathological complete response of hepatocellular carcinoma confirmed by conversion hepatectomy following atezolizumab plus bevacizumab therapy: a case report and literature review. Clin J Gastroenterol 2024;17(2):292–9. https://doi.org/10.1007/s12328-023- 01895-7.
Crossref Google Scholar
[10]

Li B, Wen J, Xu Z, et al. Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma. Clin Mol Hepatol 2024. https://doi.org/10.3350/cmh.2024.0628.
Crossref Google Scholar
iLIVER
Volume 3 Issue 4,
December 2024
Article number: 100130
DOI: 10.1016/j.iliver.2024.100130
Cite this article:
Li B, Wang Q, Hu W, et al. Comment on “Clinical outcomes and histologic findings of patients with hepatocellular carcinoma with durable partial response or durable stable disease after receiving atezolizumab plus bevacizumab”. iLIVER, 2024, 3(4): 100130. https://doi.org/10.1016/j.iliver.2024.100130

42

Views

0

Crossref

0

Scopus

Altmetrics
Received: 21 September 2024
Revised: 14 October 2024
Accepted: 16 October 2024
Published: 07 November 2024
© 2024 The Author(s). Tsinghua University Press.

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Return